Use of global assessment measures in dementia drug trials.
I argue in this paper that the use of a global clinical impression of change as a primary measure in dementia drug trials is appropriate, given that we do not yet understand clearly enough what Alzheimer's disease looks like as it gets better.
Rockwood
K
K
Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
D000544:Alzheimer Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D016896:Treatment Outcome